Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Neureiter

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
The Pharmacogenomics Journal|July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
British Journal of Cancer|May 31, 2014
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patientsK T Troppan, K Schlick, A Deutsch, et al.
Oncogene|July 7, 2010
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cellsP Desch, D Asslaber, D Kern, et al.
ESMO Open|January 5, 2021
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrenceT Magnes, S Wagner, A R Thorner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
The Pharmacogenomics Journal|July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
British Journal of Cancer|May 31, 2014
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patientsK T Troppan, K Schlick, A Deutsch, et al.
Oncogene|July 7, 2010
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cellsP Desch, D Asslaber, D Kern, et al.
ESMO Open|January 5, 2021
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrenceT Magnes, S Wagner, A R Thorner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
Pageof 4